Edition:
India

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

167.99USD
1:30am IST
Change (% chg)

$-3.73 (-2.17%)
Prev Close
$171.72
Open
$170.71
Day's High
$171.53
Day's Low
$167.00
Volume
133,675
Avg. Vol
120,576
52-wk High
$182.51
52-wk Low
$34.58

Chart for

About

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290... (more)

Overall

Beta: --
Market Cap(Mil.): $4,400.80
Shares Outstanding(Mil.): 3.26
Dividend: --
Yield (%): --

Financials

BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting

* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

16 Apr 2018

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MATURE T-AND NK-CELL LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

10 Apr 2018

BRIEF-BeiGene Appoints J. Samuel Su To Its Board Of Directors

* BEIGENE APPOINTS J. SAMUEL SU TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

03 Apr 2018

BRIEF-BeiGene Qtrly Net Loss Per ADS $2.19

* BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

01 Mar 2018

BRIEF-Wellington Management Group Llp Reports 8.39 pct Passive Stake In Beigene Ltd As Of Dec, 29, 2017

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 8.39 PERCENT PASSIVE STAKE IN BEIGENE LTD AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2EqL8XD) Further company coverage:

08 Feb 2018

BRIEF-BeiGene Announces Commercial Availability Of Vidaza In China

* BEIGENE ANNOUNCES COMMERCIAL AVAILABILITY OF VIDAZA® (AZACITIDINE FOR INJECTION) IN CHINA

06 Feb 2018

BRIEF-BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-BeiGene prices follow-on offering of 7.4 mln American depositary shares at $101 per ADS

* ‍PRICING OF FOLLOW-ON PUBLIC OFFERING OF 7. 4 MILLION AMERICAN DEPOSITARY SHARES AT A PRICE TO PUBLIC OF $101.00 PER ADS​ Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Beigene Announces Proposed Public Offering

* BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​

17 Jan 2018

Earnings vs. Estimates